Trametinib shows promise for children with relapsed or refractory juvenile myelomonocytic leukemia
The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a Phase II clinical trial, with seven of 10 patients ...
Jun 13, 2024
0
0